A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Summary

The main purpose of this study is to evaluate the safety of the study drug ramucirumab in combination with weekly docetaxel in participants with stage IV non-small cell lung cancer (NSCLC) following disease progression after prior platinum-based chemotherapy.

Timeline

Start

2016-11

Primary completion

2017-07

Completion

2018-01

Outcome

Outcome not reported

Stopped: “To pursue broader program objectives in oncology.”

Drugs

Indications